Krystal Biotech, Inc 8-K, filed May 13, 2025
Krystal Biotech, Inc. (KRYS)
8-K
2025-05-13
For: 2025-05-12
View Original
Added on
April 08, 2026
About this 8-K
Krystal Biotech, Inc filed this 8-K on May 13, 2025, reporting on events of May 12, 2025.
Items reported
- Item 7.01: Regulation FD disclosure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 12, 2025
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||||||||
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (412 ) 586-5830
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Common Stock | KRYS | Nasdaq Global Select Market | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On May 9, 2025, Krystal Biotech, Inc. (the “Company”) presented a poster entitled “Expansion of an HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases” at the Society for Investigative Dermatology (SID) 2025 Annual Meeting. A copy of the poster presented at the SID meeting is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The poster will also be available on the “Investors” section of the Company’s website at www.krystalbio.com.
The information contained in Item 8.01 of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in Item 8.01 of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data file (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: | KRYSTAL BIOTECH, INC. | |||||||||||||||||||
| By: | /s/ Krish S. Krishnan | |||||||||||||||||||
| Name: | Krish S. Krishnan | |||||||||||||||||||
| Title: | Chairman and Chief Executive Officer | |||||||||||||||||||
Expansion of an HSV-1-Based Gene Therapy Platform to Treat Hailey-Hailey and Darier Diseases Bruce Nmezi, Ph.D.1*; Mary Jane Duermeyer, B.S.1; Jorge Guzman-Lepe, M.D.1; Trevor J. Parry, Ph.D.1; Suma M. Krishnan, M.S.1 1Krystal Biotech, Inc., Pittsburgh, Pennsylvania, 15203, USA *bnmezi@krystalbio.com SID 2025 Annual Meeting POSTER #0554 Background The topical herpes simplex virus type 1 (HSV-1)-based gene therapy beremagene geperpavec-svdt (B-VEC) has been approved to treat the rare genetic skin blistering disease dystrophic epidermolysis bullosa (DEB). The underlying platform technology is being developed for additional rare skin diseases, including Hailey-Hailey disease (HHD) and Darier disease (DD). HHD and DD are inherited genodermatoses caused by pathogenic variants in the calcium ATPases ATP2C1 and ATP2A2, respectively, for which we are developing KB111 and KB112. Here, we sought to determine if these vectors are capable of transducing clinically relevant keratinocytes both in culture and in wild-type mice in order to express their encoded ATPases with minimal toxicity. Both KB111 and KB112 are capable of transducing keratinocytes and expressing their encoded ATPases with minimal toxicity in culture and in murine skin, demonstrating that Krystal’s HSV-1- based platform is well-suited for the treatment of both HHD and DD. These studies were funded by Krystal Biotech, Inc. Krystal Biotech, Inc. would like to thank Hilltop Laboratory Animals, Inc. for their contributions to the work presented here. All animal studies were performed in an AAALAC accredited facility and protocols were IACUC approved prior to initiation. All authors are current employees of Krystal Biotech, Inc. We would like to acknowledge Dr. Meghan Conner (Krystal Biotech) for drafting this poster. References: 1. Zhou M, Kang S, Xia Y, et al. ATP2C1 knockdown induces abnormal expressions of cytoskeletal and tight junction proteins mimicking Hailey- Hailey disease. Indian J Dermatol Venereol Leprol. 2024;90:722-30. Conclusions Acknowledgements/Disclosures/References KB111 Transduction Leads to Dose-Dependent ATP2C1 Expression in the Golgi of Keratinocytes Without Cytotoxicity KB112 Transduction Leads to Dose-Dependent ATP2A2 Expression in the Endoplasmic Reticulum of Keratinocytes Without Cytotoxicity 150 100 75 50 37 250 KB111 MOI 0 0.3 3 51 kDa KB111 Functional Correction in an ATP2C1 Knockdown Cell Model Figure 1. (a) Dose-dependent KB111 genomes via quantitative PCR (qPCR) and (b) ATP2C1 transgene transcripts via quantitative reverse-transcription PCR (qRT-PCR) in clinically relevant immortalized human keratinocytes after transduction. * = samples < limit of quantification (LOQ) (c, upper) Western blotting (WB) was used to verify the production of full-length ATP2C1 protein and (c, lower) protein quantification confirmed dose-dependent protein expression following transduction at different multiplicities of infection (MOIs). (d) Immunofluorescent (IF) staining revealed proper localization of KB111-expressed ATP2C1 (green) via colocalization with the Golgi marker GOLGA4 (red). DAPI (blue) indicates nuclei staining. (e) Flow cytometry demonstrated cell viability at 48 hours post-transduction, compared to mock-transduced cells or a vector control (same vector backbone as KB111 but lacking ATP2C1). a b c d Figure 3. (a) Dose-dependent KB112 genomes via qPCR and (b) ATP2A2 transgene transcripts via qRT- PCR in clinically relevant immortalized human keratinocytes after transduction. * = samples < LOQ. (c, left) WB was used to verify the production of full-length ATP2A2 protein and (c, right) protein quantification confirmed dose-dependent protein expression following transduction at different MOIs. (d) IF staining revealed proper localization of KB112-expressed ATP2A2 (red) via colocalization with the endoplasmic reticulum marker calnexin (green). DAPI (blue) indicates nuclei staining. (e) Mosmann’s Tetrazolium Toxicity assay demonstrated cell viability at 48 hours post-transduction, compared to mock-transduced cells or a vector control (same vector backbone as KB112 but lacking ATP2A2). Figure 2. (a) HaCaT cells treated with a small interfering (si) RNA against endogenous ATP2C1 (wtATP2C1) demonstrates successful knockdown (KD) via qRT-PCR 24 hours post-transduction. (b) To confirm the ability of KB111 to supplement ATP2C1 expression, codon-optimized (co) ATP2C1 transcripts were analyzed via qRT-PCR in HaCaT cells following siRNA KD and KB111 transduction. (c) It was previously shown that filamentous (F) actin is reduced in keratinocytes following ATP2C1 KD1. F-actin expression was therefore used as a readout for the ability of KB111 to functionally correct ATP2C1 deficiency in siRNA KD keratinocytes. HaCaTs were treated with a combination of siRNA and KB111, fixed in 4% formaldehyde 24 hours after treatment, and stained with the fluorescent F-actin marker phalloidin. (c, left) F-actin fluorescent intensity was quantified across multiple fields and (c, right) representative fluorescent fields are shown. KB111 treatment reversed F-actin loss induced by ATP2C1 KD. * = p < 0.05, *** = p < 0.001. KB111 and KB112 Topical Administration Result in Properly Localized Expression of Their Encoded Proteins in Wild-Type Mice with Minimal Toxicity Figure 4. (a,b) Mice were treated topically with high, mid, or low dose (a) KB111 or (b) KB112 mixed with gel to abraded skin of the dorsal thoracic region. Full- thickness skin punch biopsies were collected after 24 hours for qPCR and qRT-PCR analysis of KB111/KB112 genomes and ATP2C1/ATP2A2 transcripts. (c,d) The localization of human (c) ATP2C1 or (d) ATP2A2 was assessed via IF in topically-treated mouse skin. (e) The tolerability of KB111 was evaluated by hematoxylin and eosin staining of skin punch biopsies after a single maximum achievable topical dose. These histological findings are representative of KB112 results. 150 100 75 50 37 KB112 MOI 0 0.3 31kDa c e No KB111 No siRNA + KB111 No siRNA No KB111 + siRNA + KB111 + siRNA F- Ac tin /D AP I 40× 40× 40× 40× D A PI /A TP 2C 1 Vehicle Control KB111 High Dose 20× 20× D A PI /A TP 2A 2 Vehicle Control KB112 High Dose 20× 20× Mock MOI 1 MOI 0.3 MOI 3 ATP2C1/GOLGA4/DAPI 40× 40× 40× 40× ** ** b a b c a b Mock MOI 1MOI 0.3 MOI 3 ATP2A2/Calnexin/DAPI 40× 40× 40× 40× MOI 3 a d e 24 hours 168 hours (7 days) Vehicle KB111 20× 20× 20× 20× Vehicle KB111 d c e - - - + + - + + 0 2 4 6 8 10 F-Actin Fluorescence Fl uo re sc en ce In te ns ity ( A U) siRNA KB111 ✱ ✱✱✱✱✱✱